

BIO/SECL/TG/2025-26/56

July 08, 2025

|  |   |
|--|---|
| To,<br>The Secretary<br><b>BSE Limited</b><br>Department of Corporate Services<br>Phiroze Jeejeebhoy Towers,<br>Dalal Street, Mumbai – 400 001<br><b>Scrip Code – 532523</b> | To,<br>The Secretary<br><b>National Stock Exchange of India Limited</b><br>Corporate Communication Department<br>Exchange Plaza, Bandra Kurla Complex<br>Mumbai – 400 050<br><b>Scrip Symbol - Biocon</b> |
|--|---|

Dear Sir/Madam,

**Subject: Intimation for the Board Meeting and Earnings Conference Call for Analysts and Investors**

Pursuant to Regulation 29(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Thursday, August 07, 2025, *inter alia*, to approve and take on record the un-audited standalone and consolidated financial results of the Company for the quarter ended June 30, 2025, amongst other routine matters.

The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from Tuesday, July 01, 2025 to Saturday, August 09, 2025 (both days inclusive) in compliance with the provisions of the Code of the Company read with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015. Accordingly, the trading window will open on Sunday, August 10, 2025.

The Company will organize an Earnings Conference Call for analysts/investors on Friday, August 08, 2025. The details of the same are enclosed herewith.

The above-mentioned information will also be available on website of the Company at [www.biocon.com](http://www.biocon.com).

Request you to take the above intimation on record.

Thanking You,

For **Biocon Limited**

---

**Siddharth Mittal**  
**Managing Director & CEO**  
**DIN: 03230757**

Encl: as above



20th K.M. Hosur Road, Electronics City, Bengaluru 560 100

July 8, 2025

### Biocon's Q1 FY 2025-26 Earnings Conference Call

At 09:00 hrs. IST on August 8, 2025

The management team of Biocon Limited (BSE code: 532523, NSE ID: BIOCON) will **organize a conference call for Analysts and Investors** following the announcement of financial results for the quarter ending June 30, 2025. The call will be conducted over Zoom.

| Conference Call Details    |  |
|----------------------------|--|
| Date                       | Friday, August 8, 2025   |
| Time                       | 09:00 hrs IST  |
| Registration Link          | <a href="#">Click here</a>   |
| Recording                  | <ul style="list-style-type: none"><li>• Audio recording will be made available before the next trading day or within 24 hrs from the end of the call, whichever is earlier</li><li>• Video recording will be made available within 48 hrs from the end of the call</li><li>• Access the recordings on the Company website (Biocon &gt; Investors &gt; Financial Information &gt; Earnings Call Recordings)</li></ul> |
| Conference Call Transcript | Will be made available within 5 working days of the conclusion of the call on the Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts)   |

*Note: Participants are requested to join 10 minutes before the scheduled start time of the call.*

For further information please contact:

**Saurabh Paliwal**

Investor Relations – Biocon Limited

P: +91 80 2808 2040/ +91 95383 80801

E: [saurabh.paliwal@biocon.com](mailto:saurabh.paliwal@biocon.com)

**Safe Harbor:** Certain statements that may be made in the conference call may be forward-looking based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and overseas, and changes in the foreign exchange control regulations in India. Neither Biocon, nor our directors, nor any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in the conference call.